D-alanine added to antipsychotics for the treatment of schizophrenia

Department of Psychiatry, Harbor-UCLA Medical Center, Torrance, California 90509, USA.
Biological Psychiatry (Impact Factor: 9.47). 03/2006; 59(3):230-4. DOI: 10.1016/j.biopsych.2005.06.032
Source: PubMed

ABSTRACT Hypofunction of the N-methyl-d-aspartate (NMDA) subtype glutamate receptor had been implicated in the pathophysiology of schizophrenia. Treatment with D-serine, glycine, endogenous full agonists of the glycine site of the NMDA receptor (NMDA-glycine site), D-cycloserine, a partial agonist, or sarcosine, a glycine transporter-1 inhibitor, improves the symptoms of schizophrenia. D-alanine is another endogenous agonist of the NMDA-glycine site that might have beneficial effects on schizophrenia.
Thirty-two schizophrenic patients enrolled in a 6-week double-blind, placebo-controlled trial of D-alanine (100 mg/kg/day), which was added to their stable antipsychotic regimens. Measures of clinical efficacy and side effects were determined every other week.
Patint who received D-alanine treatment revealed significant reductions in their Clinical Global Impression Scale and Positive and Negative Syndrome Scale (PANSS) total scores. The Scale for the Assessment of Negative Symptoms and PANSS subscores of positive and cognitive symptoms were improved. D-alanine was well tolerated, and no significant side effect was noted.
The significant improvement with the D-alanine further supports the hypothesis of hypofunction of NMDA neurotransmission in schizophrenia and strengthens the proof of the principle that NMDA-enhancing treatment is a promising approach for the pharmacotherapy of schizophrenia.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Hydrogen peroxide (H2O2) is produced endogenously in a number of cellular compartments, including the mitochondria, the endoplasmic reticulum, peroxisomes, and at the plasma membrane, and can play divergent roles as a second messenger or a pathological toxin. It is assumed that the tuned production of H2O2 within neuronal and nonneuronal cells regulates a discreet balance between survival and death. However, a major challenge in understanding the physiological versus pathological role of H2O2 in cells has been the lack of validated methods that can spatially, temporally, and quantitatively modulate H2O2 production. A promising means of regulating endogenous H2O2 is through the expression of peroxide-producing enzyme d-amino acid oxidase (DAAO from Rhodotorula gracilis lacking a peroxisomal targeting sequence). Using viral vectors to express DAAO in distinct cell types and using targeting sequences to target DAAO to distinct subcellular sites, we can manipulate H2O2 production by applying the substrate d-alanine or permeable analogs of d-alanine. In this chapter, we describe the use of DAAO to produce H2O2 in culture models and the real-time visual validation of this technique using two-photon microscopy and chemoselective fluorescent probes.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Contributions to neuroscience are necessary to understand the behavior of the brain. Powerful analytical techniques are needed to monitor neuroactive molecules and their concentrations in biological samples (fluids, cells, and brain tissues). Capillary electrophoresis (CE) is well known for its high resolution power, short analysis times, and low consumption of reagents and samples. It presents analytical advantages for the determination of neuroactive molecules not easily determined by other analytical techniques. CE also offers the possibility of controlling more than one neuroactive molecule at a time, making it interesting to detect changes as a result of a stimulus. CE is well established to accomplish enantioseparations, contributing a better understanding of the properties of a neuroactive chiral molecule. This review focuses on the most relevant articles published from January 2008 to July 2014, based on the determination in biological samples of potentially interesting molecules in neuroscience using CE and microchip-CE.
    TrAC Trends in Analytical Chemistry 02/2015; DOI:10.1016/j.trac.2014.12.008 · 6.61 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: SOUHRN Sdělení se zabývá definicí a stanovením farmakorezistentní schizofrenie a možnostmi její léčby. V poslední době se při hodnocení farmakorezistence soustřeďujeme hlavně na přetrvávající příznaky, protože máme k dispozici léčebné přístupy, které preferenčně ovlivňují některé příznaky (pozitivní, negativní, kognitivní deficit, afektiv-ní). Z léčebných postupů je nejprve věnována pozornost užití vysoký dávek, tj. dávek vyšších než maximálních oficiálně uvedených. Další možností je změna stávající léčby na klozapin a polyfarmakoterapie. Klozapin je v této indikaci stále považován za zlatý standard. Polyfarmakoterapie, hlavně kombinace antipsychotik i augmentace antipsychotik látkami, které nejsou primárně určeny k léčbě psychóz, je velmi častá. Z dostupných dat vyplývá, že u stabilizovaných nemocných se schizofrenní poruchou je často polyfarmakoterapie nadbytečná. Měla by být proto zvažována velmi pečlivě a individuálně s ohledem na přetrvávající symptomatologii. Klíčová slova: farmakorezistentní schizofrenie, antipsychotika, vysoké dávky, klozapin, polyfarmacie, kombi-nace antipsychotik, augmentace antipsychotik.